---
title: The July 2023 Quality Digest | PharMerica
---

Catch up on the latest clinical and regulatory long-term care news in the July edition of The Quality Digest!

| View in browser July 2023   The Quality Digest The Quality Digest is a recap of content aimed at advancing clinical care and excellence and keeping you informed about the latest regulations. FDA Approves Two RSV Vaccines    Both GSK and Pfizer recently won FDA approval for RSV vaccines and are planning to begin offering them this fall. The CDC's Advisory Committee on Immunization Practices (ACIP) met this month and, upon reviewing the available data, drafted recommendations for use of these newly approved vaccines in adults 60 and older. These recommendations are pending approval from the CDC Director and the Department of Health and Human Services. If approved, more than 55 million adults will be eligible to receive an RSV vaccine.  READ MORE Did You Know?: Order of Administration for Eye Drops and Inhalers   Because ophthalmic drugs and inhaled drugs generally work locally, order of administration can be integral when multiple products are to be administered at once. Learn more in PharMerica's new guide. READ MORE Onco360 Now Offering Jakafi, Ayvakit, and Epkinly   Onco360 recently obtained limited distribution drug access for the following products:    Ruxolitinib (Jakafi®), approved for the treatment of: intermediate or high-risk myelofibrosis; polycythemia in adults with an inadequate response to or intolerant of hydroxyurea; steroid-refractory acute graft-vs-host disease in patients 12 and older; and chronic graft-vs-host disease when systemic therapy has failed in patients 12 and older.    Prescribing Information for Jakafi Ayvapritinib (Ayvakit®), approved for the treatment of: some cases of metastatic or unresectable gastrointestinal stromal tumors (GIST) in adults; advanced systemic mastocytosis in adults; and indolent systemic mastocytosis in adults.   Prescribing Information for Ayvakit Epcoritamab-bysp (Epkinly™), approved for the treatment of: relapsed or refractory diffuse large B-cell lymphoma in adults and high-grade B-cell lymphoma in adults after two or more lines of systemic therapy.   Prescribing Information for Epkinly   Compliance Cue: Expanded Psychotropic Definition   Updated surveyor guidance and statements from CMS about stepped-up oversight are driving increased scrutiny of psychotropics. To help facilities understand the top F-tags for this drug class, PharMerica has developed a series of Compliance Cues. This guide provides information on F758, which provides an expanded definition for this drug class and guidance on other medications used for psychotropic purposes.  READ MORE Join Our Upcoming Webinars! Improving Outcomes in I/DD: Value-Based & Home-Based Primary Care   Tuesday, July 18, 2023 1pm ET   Register Now Survey Activity State by State: A Town Hall with DONs and Administrators   Tuesday, July 25, 2023 1pm ET   Register Now Six Strategies for Successful Operational & Clinical Outcomes to Manage the Conversion to MDS 3.0 1.18.11   Tuesday, August 8, 2023 1pm ET   Register Now Understanding Loss Risks in Assisted Living During Transitions in Care   Tuesday, August 22, 2023 1pm ET   Register Now Podcast Episode 14: DONs & Administrators Working Better Together Listen to our latest "Spoonful of Sugar" podcast, recorded LIVE from last week's NADONA National Conference, in which NADONA's Robin Arnicar and Sherrie Dornberger talk with McKnight's John O'Connor and PharMerica's TJ Griffin about strategies to generate collaboration between DONs and administrators to increase efficiency and improve outcomes.  LISTEN NOW PharMerica, 805 N. Whittington Pkwy, Louisville, KY 40222, United States Unsubscribe Manage preferences |
| --- |